FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1641-1643 April 13, 2006 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Armstrong, D. K. PubMed Citation

To the Editor: Armstrong et al. (Jan. 5 issue)¹ may have overestimated the benefit of intraperitoneal therapy in ovarian cancer, as compared with standard intravenous carboplatin plus paclitaxel. We undertook an exploratory cross-trial analysis (Figure 1) comparing intraperitoneal cisplatin plus paclitaxel in the patients in the study by Armstrong et al. with intravenous carboplatin plus paclitaxel in 392 patients with a similar stage of ovarian cancer in the previous study by the same cooperative group.² In both studies, the median overall survival in the control group receiving intravenous cisplatin plus paclitaxel was similar: 49.7 months and 48.7 months, . . . [Full Text of this Article]

This article has been cited by other articles:

• Lu, Z., Tsai, M., Lu, D., Wang, J., Wientjes, M. G., Au, J. L.-S. (2008). Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer. J. Pharmacol. Exp. Ther. 327: 673-682 [Abstract] [Full Text]  
• Swart, A. M. C., Burdett, S., Ledermann, J., Mook, P., Parmar, M. K. B. (2008). Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review. Ann Oncol 19: 688-695 [Abstract] [Full Text]  
• Aletti, G. D., Gallenberg, M. M., Cliby, W. A., Jatoi, A., Hartmann, L. C. (2007). Current Management Strategies for Ovarian Cancer. Mayo Clin Proc. 82: 751-770 [Abstract] [Full Text]  
• Armstrong, D. K., Brady, M. F. (2006). Intraperitoneal Therapy for Ovarian Cancer: A Treatment Ready for Prime Time. JCO 24: 4531-4533 [Full Text]